Icovamenib

Small molecule

Also known as BMF-219

Partialsignal

Evidence outlook · lead readout

NCT05731544 · Type 2 Diabetes Mellitus

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT05731544: The diabetes part of this study was randomized, double-blind and placebo-controlled, and measured HbA1c, the standard outcome for type 2 diabetes. The sponsor reports that HbA1c fell significantly more than with placebo, but only in patients who completed most of their dosing, and no power calculation or planned enrolment was found in the sources checked.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Type 1 Diabetes · Phase 2

Company guidance: topline data expected second quarter of 2027 (Biomea Fusion, 10 Nov 2026). “Enrollment ongoing in the Phase II COVALENT-212 clinical trial evaluating icovamenib in patients with T2D not achieving glycemic targets on GLP-1 receptor agonist (“GLP-1 RA”)-based therapy; topline data expected in the second quarter of 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Type 1 Diabetes
Type 2 Diabetes
NCT07502508 · Biomea Fusion Inc.
2026-04-30 – 2027-07 · Type 2 Diabetes
What this study did
Phase 1/2 (1)
Type 2 Diabetes
Phase 1 (3)
Other / comorbidity
NCT07254286 · Biomea Fusion Inc.
2025-09-11 – 2026-01-14 · Healthy Volunteer
What this study did
NCT05631574 · Biomea Fusion Inc.
2023-01-12 – 2025-01-15 · Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Icovamenib: this drugPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
Revumenib
Approved(overall)
Small moleculeMenin
Weak signal(overall)
No reviewed efficacy summary in this indication
Ziftomenib
Approved(overall)
Small moleculeMenin
Weak signal(overall)
No reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Icovamenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 2Type 2 DiabetesActive not recruiting
Est. primary completion 2027-03 · NCT07502495 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Type 2 DiabetesRecruiting
Est. primary completion 2027-06 · NCT07502508 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 April 2026Topline resultPositive 52-week Phase 2 COVALENT-112 results in type 1 diabetes